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Neuronal ceroid lipofuscinoses (NCL) are rare neurological disorders with a uniform phenotype, caused by mutations in seven known genes.
NCL provide a unique model to characterize molecular pathways critical for normal neuronal development and pathological neuronal
degeneration. Systems biology based approach utilizes the rapidly developing tools of genomics, proteomics, lipidomics and metabolomics and
aims at thorough understanding of the functions of cells, tissues and whole organisms by molecular analysis and biocomputing-assisted modeling.
The systems level understanding of NCL is now possible by utilizing different model organisms. Initial work has revealed disturbed metabolic
pathways in several NCL disorders and most analyses have utilized the infantile (INCL/CLN1) and juvenile (JNCL/CLN3) disease modeling and
utilized mainly human and mouse samples. To date, the data obtained from transcript and lipidomic profiling has pinpointed the role of lipid
metabolism and synaptic function in the infantile NCL. Changes in glutamate utilization and amino acid metabolism have been a common theme
emerging from the transcript and metabolite profiling of the juvenile NCL. Further experimental models are being developed and systematic
sample collection as well as data integration projects are needed. The combined analyses of the global information should provide means to expose
all the NCL-associated molecular pathways.
© 2006 Elsevier B.V. All rights reserved.Keywords: Neuronal ceroid lopifuscinosis; Global strategies for NCL; NCL systems biology1. Introduction
The Neuronal ceroid-lipofuscinoses (NCLs) are collectively
the most common inherited progressive encephalopathy of
childhood, with a frequency of 7–8 per 100,000 live births
[1,2]. All forms of NCLs are characterized by progressive
neuronal death in the central nervous system (CNS), leading to
manifestation of epilepsy and progressive mental and physical
decline [3,4]. These rare diseases, caused by mutations in seven
known genes, provide a unique model to characterize molecular
pathways critical for normal neuronal development and
pathological neuronal degeneration. Three early clinical types,
congenital NCL, CLN1 and CLN2, are caused by deficiencies⁎ Corresponding author. Tel.: +358 9 4744 8392; fax: +358 9 4744 8480.
E-mail address: Anu.Jalanko@ktl.fi (A. Jalanko).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.09.001of lysosomal enzymes cathepsin D [5–8], palmitoyl protein
thioesterase 1 (PPT1) [9–11] and tripeptidyl peptidase 1 (TPP1)
[12,13]. Three NCL types, CLN3, CLN6 and CLN8, are caused
by mutations in genes encoding novel transmembrane proteins
of which CLN3 is lysosomal and both CLN6 and CLN8
residents of the endoplasmic reticulum (ER) [14–22]. CLN5 is
encoding a polypeptide that is found as a soluble but possibly
also a membrane-bound lysosomal protein [23–25].
All known NCL-proteins are expressed ubiquitously, but
their defective functions produce dramatic consequences solely
in neurons. Different explanations are proposed for this neuron-
specificity: neurons may simply be more sensitive to storage
materials. Alternatively, NCL proteins may be linked to the
development of the nervous system or involved in so far
uncharacterized neuron-specific metabolic pathways. Recent
investigations have provided new data on the functional aspects
935A. Jalanko et al. / Biochimica et Biophysica Acta 1762 (2006) 934–944of the NCL proteins. Especially the research of the most
common form, JNCL/CLN3 has provided novel links between
the CLN3 protein and cytoskeleton connected to defects in
membrane and ion transport [26–30]. However, it remains
obvious that more system-wide, non-hypothesis-based strate-
gies are needed to expose all the NCL-associated pathways.
Experimental species, including both naturally occurring and
specifically targeted mouse models for NCL have provided
excellent tools to address the molecular pathways behind
various forms of NCL. So far the targeted knock-out and knock-
in mouse models exist for Cln1 and Cln3 and knock-out models
for Cln2, Cln5 and cathepsin D [31–37]. Naturally occurring
mouse mutants interrupting the homologous CLN gene exist for
Cln6 (nclf) and Cln8 (mnd) [38,39]. Collectively these mouse
models represent an invaluable resource for investigating the
molecular pathogenesis in these devastating neurodegenerative
disorders and novel information has already emerged from
mouse studies of NCL. This is well exemplified by the work
that has established the role of selective involvement of
GABAergic interneurons combined with disturbances in the
thalamocortical circuits in the neuronal pathogenesis of NCL
[40–47]. Critical for future treatment of these devastating
diseases are the gene therapy trials carried out in two mouse
models which have also enabled the first human trials [48–51].
The potential of the NCL mouse models for genome-wide
analyses to define all involved pathways still remains to be
utilized. Except rodent models, the yeast model has exposed
critical pathways in NCL, even helped to identify the primary
gene defects [26].
Systems biology-based approach uses the rapidly develop-
ing tools of genomics, proteomics, lipidomics and metabo-
lomics and aims at thorough understanding of the functions of
cells, tissues and whole organisms by “holistic” molecular
analysis and bio computing-assisted modeling. The systems
level understanding of a biological organism will be enabled
by combining data collected at different levels of the
biological system, using molecular, cellular, and physiological
methods. The basic technologies for global analyses of mRNA
and protein levels as well as genome-wide strategies to
systematically block the transcription of selected sets of genes
are becoming available for investigators [52–56]. Additional-
ly, mass spectrometry and NMR spectroscopy have proven
feasible to screen the changes in lipids and solute metabolites
in a system-wide manner and form the backbone methods for
lipidomics and metabolomics [57,58]. Finally advanced
imaging technologies facilitate detailed analyses of specific
brain regions both in humans and in experimental animals,
like exemplified by the recently produced first versions of the
3D map of human and C57/BL mouse brain, produced by
magnetic imaging [59–61]. All systems biology approaches
create huge amount of data, which needs to be carefully
quality controlled and analyzed with advanced tools of
biocomputing in order to decipher the metabolic events
within the organism and to evaluate the significance of
findings in a given system. This review aims to summarize
the genome wide approaches used in the analyses of NCL and
corresponding mouse models.2. Utilization of global gene expression profiling to
approach the disturbed metabolic pathways in NCL
The mouse is particularly suitable for the analysis of gene
expression since tissues from all stages of development and
many different strains and mutants are available. To date, nine
mouse models for neuronal ceroid lipofuscinoses (NCL) have
provided us with highly accurate tissue phenotypes but so far
have not significantly contributed to the pathways involved or
to the more detailed understanding of molecular pathogenesis in
CNS. Only a handful of reports have taken genome-wide
strategies to dissect the disease process in details, most studies
have focused on the establishing the relevance of mouse models
for human diseases. However, first reports of transcript profiles
collected from various brain regions have helped to provide
some clues of affected metabolic pathways in three of these
mouse models, providing potential targets for more focused
analyses [32,36,62–65].
2.1. Transcript profiling in Cln1 deficient mouse models
The Cln1-knockout mice homozygous for a truncation of the
Cln1 gene product, were first analysed for global gene
expression changes from whole brains at the age of 10 weeks
[62] (Table 1). The analysis resulted in the identification of 20
genes with altered expression >1.5 fold and provided
immunoblotting data that supported the observed expression
changes of selected genes. The genes with transcript levels
deviating from controls are known to be involved in various
cellular pathways, including lipid metabolism, trafficking, glial
activation and calcium homeostasis, all of which have been
connected to the tissue pathogenesis of human INCL [2,66–68].
In another study, targeted to the cortical region and reporting
transcript profiles in 6 month old Ppt1Δdex4 mice [32],
significant changes were observed for total of 234 genes
among which 195 were upregulated (Table 1). The up-regulated
genes partitioned in a wide variety of developmental, cellular,
physiological and metabolic processes. This study employed a
statistical algorithm and rigorous two-step data-filtering process
and could pinpoint immune response processes as predominant
disturbed pathways in the knockout mice. The signs of cortical
inflammation were also analyzed by immunohistochemistry and
the data implied that inflammation appeared prior to neurode-
generation in Ppt1Δdex4 mice. Comparison of the two transcript
profiling analyses does not pinpoint changes in common genes
but both highlight the changes in inflammation related
molecular pathways.
2.2. Transcript profiling in Cln3 deficient models
For CLN3 deficiency, the mouse was not the first organism
to be utilized in global gene expression profiling. The early
analysis utilizing the S. cerevisiae knockout model for the Cln3
homolog Btn1p [26], deserves special attention. These first
analyses actually brought up implications that the CLN3 protein
is involved in cytoskeletal dynamics and this has been
replicated more recently in mammalian cell models [28,69].
Table 1
Summary of Gene expression profiling in mouse models of NCL
Mouse Age Brain region Samples Chip Data analysis Differentially expressed
genes
Affected
pathways
Ref.
Cln1 10 weeks whole 3×3 Affymetrix U74 MAS 5 20 (>1.5) ND [62]
Ppt1Δdex4 6 months ctx 2×5 Affymetrix U74Av2 MAS 5, RMA Bioconductor
GeneSpring 6.0+additional
234 (ss) 14 [32]
Cln3 10 weeks whole 3×3 Affymetrix U74 MAS 5 14 (>1.5) ND [62]
Cln3 10 weeks cb 2×3 Affymetrix
Mu19K
MAS 5 756 (>2.0) 14 [63]
Cln3 10 weeks retina 2×3 Affymetrix
Mu19K
MAS 5 285 (>2.0) 12 [64]
Cln3 E16.5 ctx neurons 2×8 Affymetrix 430 A2.0 MAS 5 GeneSpring 6.2.1. 88 (ss) 7 [65]
1 3 months ctx 2×5 Affymetrix MAS 5 016 (>2.0) 3 [36]
4.5 months ctx U74Av2 68 (>2.0)
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different types of gene expression profiling sets (Table 1).
Firstly, the whole brains of 10 week old Cln3 knockout mice
and wild-type mice were analyzed using a high-density
oligonucleotide array [62]. In this array set 14 genes with
altered expression >1.5 fold was identified and two of these
genes were associated to neurotransmitter metabolism and two
with glutamate utilization. The downregulation of membrane-
bound and soluble catechol-o-methyltransferase (COMT) was
verified also by immunoblotting. Another report presented the
gene expression changes from the cerebellum of 10 week old
Cln3 knockout mice [63]. This experiment was performed
with a different type of oligonucleotide array set (Table 1) as
compared to the previous report [62]. The cerebellum array
revealed 756 genes with reproducible change in expression of 2
fold or more. The genes were assigned to 14 different functional
classes including trafficking at the synapse, lipid metabolism,
inflammatory response, energy metabolism, cytoskeleton, cell
death and amino acid metabolism, many of which have been
connected to Cln3 deficiency [30]. Gene expression micro-
arrays have also been utilized to assess the changes expressed in
the whole eye, a characteristic target organ in human CLN
phenotype, of the Cln3 knockout mouse [64], revealing 285
genes with altered transcript levels. This work used similar
chips and data analysis procedures as the cerebellum study and
the authors identified 18 genes that did not appear as changed in
the transcript profiles of cerebellum. Particularly, downregula-
tion of genes associated with mitochondrial energy production
in the mitochondria was considered specific to the eye. Changes
in Mitochondrial energy production have been previously
detected in human NCL [66]. A very recent transcript profiling
study utilized Cln3 deficient mouse cortical neurons and
implicated disturbances in mitochondrial, cytoskeletal and
synaptic functions. This report provided the first functional
data supporting the transcript profiling of the Cln3 deficient
mouse model [65]. Similarly to the Cln1 data, no single
similarly affected genes can be detected in the four different
microarray reports assessing the Cln3 deficiency. The exami-
nation of the affected molecular pathways in the different
studies suggests a link between mitochondrial dysfunction and
cytoskeleton-mediated presynaptic inhibition behind this mouse
model of NCL.2.3. Transcript profiling in Cln5 deficient mouse model
Gene expression profiling for the Cln5 knockout mouse was
performed utilizing similar sampling, gene chips and data
analysis as with the Ppt1Δdex4 mouse [32,36] except that the
mice were analyzed at two different ages, 3 and 4.5 months. The
expression array data revealed changes of >2 fold for 16 genes
in the cerebrums of the 3 month-old knock-out mice and in the
4.5 month-old mice a total of 68 genes showed altered
expression levels. The affected molecular pathways were
further analyzed in a similar manner as in the case of the
Ppt1Δdex4 mice and the pathway analysis indicated upregulation
of pathway components related to inflammation and down-
regulation of myelin pathway components, evident in both age
groups [36].
3. Proteomic tools for the analysis of disease mechanisms in
NCL
3.1. Proteomics and brain diseases
Equally to transcript profiling, proteomic profiling should
provide information on the disease process in NCL. The
proteins defective in NCL reside in the secretory pathway of the
cell and to date, CLN2, CLN3 and CLN5 have shown some
evidence to be interconnected [25]. System-wide analysis of
proteomic alterations is so far missing and should expose novel
metabolic connections for the NCL disorders. Importantly,
proteomics is the only way to study post-translational
modifications of proteins, for example phosphorylation and
glycosylation, being of central importance at the functional
level. In order to cover the complexity and dynamics of the
eukaryotic proteome, multiple complementary techniques have
been developed, and many of the state-of-the-art methods are
only facilitated by the recent advances in mass spectrometry
(MS) [70–72].
Systems level proteomics, particularly, the brain proteomics
is at its initial state [56,73,74]. Major international efforts to
promote education and knowledge in proteomics and to
accelerate and develop proteomics research have been initiated:
the European Proteomic association (EuPA) was established in
2001 and the Human Proteome Organization (HUPO) in 2001
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on analyzing the brain proteome in health and disease [76,77].
Brain proteomics have so far provided invaluable information
on the protein profiles of normal brain tissue as well as for some
disease-specific alterations in neurological disorders [78–83].
The emerging specific applications of proteomics, including
techniques to study the brain lysosomal proteome, synaptic
proteome, or synaptic phosphoproteome, have great potential in
providing an insight into physiological and pathological events
occurring in NCL, many related to lysosomal mechanisms
[74,84–86].
3.2. Proteomic studies on NCL diseases
In contrast to many other NCL forms, for which the
causative gene defects were identified by genome-wide
mapping and positional cloning, the molecular cause of late
infantile NCL (CLN2) was initially revealed by proteomics, by
2D- gel electrophoresis: Tripeptidyl peptidase I (TPPI) spot was
absent from the lysosomal proteome of CLN2 patient tissues
[12]. Later, 2D-gel electrophoresis of the human brain mannose-
6-phosphoproteome revealed novel mannose-6-phosphate con-
taining proteins which could be considered as potential
candidates for additional NCL forms, and this study confirmed
the soluble lysosomal nature of CLN5 protein [85]. Moreover,
2D-gel electrophoresis has been used to track down the
metabolic defects in CLN6 patient tissues, where MnSOD
was found to be increased [87].
Proteomic approach on the systems level can now increas-
ingly be applied in research of NCL diseases thanks to the
availability of good and well-characterized mouse models (see
above). The mouse models facilitate standardized collection of
samples, analysis, and comparison of results under such strictly
controlled circumstances, which would never be possible with
the rarely available patient material. Moreover, longitudinal
studies at different stages of the disease process are enabled by
the mouse models of NCL. Within the EU funded research
project “NCL-models” (www.nclmodels.org), we aim to reveal
disease-specific alterations in the brain proteome by comparing
the brain protein profile of NCL mice and controls at different
stages of the disease. Moreover, we will search for common
themes in the proteomic changes shared by the different NCL
mouse models. By these studies we should be able to obtain
information on the affected metabolic events, the temporal
sequence of the observed alterations, and, most importantly, on
the similarities of neuronal defects between different forms of
NCLs.
4. The emerging field of lipidomics
4.1. Lipidomics
The crucial role of lipids within cells is demonstrated by
multiple human diseases that involve disruption of lipid
metabolic pathways; such as cancer and neurodegenerative
diseases [57,88–91]. The recent technical advances in liquid
chromatography and mass spectrometry have facilitated thesystems level analysis of lipids [57,92,93]. Importantly, many
critical brain functions are based on coordinated molecular
events at the synapse and accumulating evidence both from in
vitro cellular and in vivo mouse studies have linked the
molecular defects in NCL disorders closely to the disturbed
synaptic functions [94–97]. These events occur in regulated
lipid microenvironments with highly specific lipid composition
and lipid–protein interactions [98,99].
4.2. Lipidomics and NCL diseases
The lipid profiles of the NCL brain have previously been
studied in autopsy tissues from humans and animals with NCL,
and conventional analytical methods have indicated alterations
in many lipid classes, including polyunsaturated fatty acids,
cholesterol, sphingolipids, triacylglycerols, lysophosphatidic
acid and dolichols [100–103]. More recently, the early data on
dolichol accumulation and lack of polyunsaturated fatty acids in
NCL tissues have been supported by quantitative studies using
state-of-the-art methods: FACE technique (fluorophore assisted
carbohydrate electrophoresis) revealed a striking accumulation
of lipid-linked oligosaccharides in six mouse models of NCL,
and it was suggested that the lipid-linked oligosaccharides
arouse from dolichol-linked sugars during the lysosomal
degradation of autophagosomes [104]. Finally, quantitative
MS analysis of brain lipids has revealed complex and dramatic
alterations in the molecular composition of phospholipids,
neutral sphingolipids and sulfatides, particularly in the poly-
unsaturated fatty acid species of these lipids, in patients with
CLN1 and CLN8, but not in patients with CLN2 or CLN3
[68,92,105]. These studies indicating clear alterations in the
lipid composition of NCL brains were performed on human
autopsy material, for which the post mortem delay and storage
conditions vary. Thus, based on the first promising results and
the possibility to utilize the animal models, the emerging field of
lipidomics is likely to provide an invaluable view into the
pathogenetic mechanisms of NCL diseases.
5. Metabolomics: Global analysis of small molecules
Metabolomics refers to characterization of biological
variation in a small molecular weight metabolite level
[58,106,107] and metabolic disorders often result in the
secretion of abnormal metabolites into the serum or urine of
patients. It has been long known that the storage material in all
NCLs is highly insoluble and the early studies of NCL patients
could only describe the accumulation of abnormal dolichols in
the urine (see previous section). More recent analyses have
utilized autopsy brain samples of CLN1 and CLN3 deficient
patients and discovered significantly altered neuronal metabo-
lite profiles in CLN1 [108]. Utilization of the Cln3 mouse
model brought up the observation of GAD65 autoantibodies in
the serum of Cln3 deficient mice and this was also observed in
JNCL patients [109,110]. No system level screening of serum or
urinary metabolites has yet been performed in NCL patients, but
interestingly, the screening of amino acid levels in JNCL patient
sera apparently led to the discovery of abnormal arginine
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spectroscopic analysis of biofluids and tissue extracts, in
conjunction with multivariate statistics have been demonstrated
to be highly discriminatory for neurological diseases [112]. For
NCL, the first metabolomics study utilizing the multivariate
statistical approach was performed for the mnd mouse model,
harboring a mutation in the Cln8 gene and representing a model
for the CLN8/Northern epilepsy. A number of altered
metabolite profiles were identified in the mnd mouse brain
and blood plasma, exemplified by increased glutamate and N-
acetyl-aspartate (NAA), and decreased creatine and glutamine
[113]. A more recent metabolomics approach, based also on
high resolution solution 1H NMR spectroscopy in conjunction
with statistical pattern recognition revealed profound metabolic
changes in 1–6 month-old Cln3 knock out mouse of cortex,
cerebellum and remaining regions of the brain [114]. More
specifically, concentrations of glutamate were increased in all
areas and time points whereas those of GABA were decreased
relative to wild type. These changes can potentially be linked to
the observed upregulation of glutamic acid decarboxylase
autoantibodies (GAD65 autoantibodies) detected in the tissues
of the Cln3 knockout mice [111]. Also, this type of insult may
be explained by the documented selective loss of GABAergic
interneurons in the Cln3 knockout mice, although this is
detected only at the age of 7 months [33]. Further variations in
myo-inositol, creatine and NAA were identified, possibly
reflecting an early stage glial activation in these knockout
mice [44]. Importantly, the metabolic changes could be shown
to be independent from the normal aging process.
6. Utilization of RNAi to study the role of different genes in
NCL
The animal models for NCL offer the possibility to screen
the metabolic defects in a disease state. The brain is a very
delicate organ and in the NCL, the primary functional defect
may be masked by a general neuronal insult. The analyses of
affected metabolic pathways in NCL would greatly benefit if the
analyses were performed both to diseased tissue and to normal
tissue or cells that have been induced an instant shutdown of the
disease gene. RNAi is a gene silencing technology that is
spreading rapidly to nearly every aspect of biomedical research
[55,115,116]. RNAi utilizes sequence-specific short interfering
RNA (siRNA), known to form an RNA-induced silencing
complex with other cellular proteins, leading to sequence-
specific degradation of RNA [117]. RNAi technology has been
utilized to study the role of different genes in the disease
pathogenesis and for the identification of new therapeutic
targets for metabolic diseases. To date, great success has been
accomplished in the utilization of this technology in for
example analysis of insulin signaling in diabetes [118]. C.
elegans has been widely utilized in the RNAi screens,
exemplified by the C. elegans ORFeome resource, offering
the genome-wide C. elegans RNAi library [119,120]. For the
NCL diseases, different model organisms are being developed
and it should be of interest to utilize the RNAi technology for
gene silencing in each NCL. Many of the NCL proteins arelikely to interact or at least the different NCL disorders are
expected to show similar metabolic disturbances. This technol-
ogy offers the possibility to silence the NCL genes cross the
disease spectrum and should offer a highly feasible tool to
assess the combined effects of the silencing of NCL genes.
Naturally, cross-breeding of different NCL model organisms
will lead to more accurate answers at the disease level but this
route is much more tedious, expensive and time consuming and
not suitable as an initial screening tool, making specific gene
silencing with RNAi as a lucrative option.
7. Data analysis and databases
The interpretation of genome-wide data remains a major
challenge because of the complexity of the underlying
biological networks and problems in sufficiently accurately
targeted sample collection of relevant tissues like brain or eye.
Transcriptional profiling of CNS samples has proven to be a
challenging task due to the complexity of the tissue and
problems in obtaining sufficiently clean cellular populations,
the heterogeneity of RNA source, diluting the differences in
transcript levels. Characteristic for all studies described here,
the changes seen in the transcript profiles of individual genes
have been marginal and often statistically not significant
[reviewed in [121–123]. Further, the transcript levels of brain
specific genes are often low, requiring usage of specific
statistical methods. Finally, none of the studies so far has
addressed sufficiently the different developmental stages of
CNS, a critical parameter for the disease pathogenesis of NCL.
In order to recapitulate the possibly perturbed functional
biological networks involved in disease process, a detailed
pathway analysis is required [124]. To obtain meaningful
expression data, it is crucial to develop standardized approaches
for study design, annotation of resources, quality control,
statistics, data registration and storage. The success requires
accurate, quality controlled technology and good practices have
been adopted [125,126].
Another critical issue is the data interpretation. A wide
diversity of statistical methods have been applied for classifi-
cation and recognition of expression profiles. The data
transformation steps include image acquisition and segmenta-
tion and although many current methods and software packages
offer automatic image processing, no consensus exists for the
best possible logistics and the problems encountered in various
steps of data cleaning have generated a large amount of
literature [126,127]. Finally, extensive developmental work is
ongoing in the functional classification of the initially identified
involved biological processes. Currently, the microarray data is
most often linked to Gene ontology (GO) terms, constituting
standardized nomenclature for biological processes, molecular
functions and cellular components [128,129]. Several statistical
tools have been developed that link microarray experimental
data to GO terms in an automated way (www.geneontology.org/
GO.tools.shtml). New biocomputational approaches aim at
relating the gene expression patterns with functional networks
and a wide variety of tools have been introduced to connect the
array data to documented biological pathways [127,130].
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by NCL mutations can be addressed using also other types of
genome-wide tools and methods of bioinformatics, reaching
beyond the comparative analyses of transcript profiles. A
comprehensive view of the putative protein interactions is
possible using sequence information from multiple species and
bioinformatics plays a key role in the construction of genetic (or
protein) networks [131]. Homology searches can identify
orthologues and paralogues of genes with known functions
and shared regulatory motifs combined with coordinated
expression levels are good indicators of genetic networks.
Phylogenetic profiling looks for genes showing the same pattern
of presence or absence across multiple genomes [132]. The
Rosetta Stone (domain fusion) method identifies proteins that
are separate in one organism but fused in another [133]. Finally,
the gene neighbour method identifies genes that are chromo-
somally close across many species. Further validation is
possible when identified genes have a known function. In this
event, one can compare the keyword annotations for the
clustered genes in one or more of the current databases. Data
from expression arrays can be extended by using algorithms
aiming at identification of common promoter and enhancer
regions on co-expressed genes in critical tissues or cells
revealing cross-talking genes under similar cis-regulation
[134,135]. The shared transcriptional elements in promoter
and enhancer regions can be identified by utilizing both
experimentally derived transcription factor binding site libraries
(Transfac and JASPAR) and ab initio motif finding techniques
(AnnSPEC, AlignACE, CompareACE) in the sets of genes
grouped by co-expression or by GO-based biological pathways.
In order to increase the specificity of the ambiguous
transcription factor binding motifs, comparative genomics/
phylogenetic footprinting techniques can also be used. It seems
obvious that various strategies utilizing advanced tools of
biocomputing and accumulating data of publicly accessible
databases will shed new light also on the molecular networks of
CNS harmed by NCL mutations. Again, a co-ordinated data
collection and integrated data analyses across different NCL
types and animal models would greatly benefit the field.Fig. 1. Current status of gl8. Summary and future prospects
The unraveling of the molecular mechanisms that underlie a
complex process, such as neuronal development or neurodegen-
eration, is a formidable challenge. NCL disorders comprise a
genetically heterogenic group of diseases that still result in a
relatively uniform phenotype in the CNS, characterized by a
progressive and selective neuronal loss. All the proteins
underlying NCLs, i.e. PPT1, TPP1, CLN3, CLN5, CLN6,
CLN8 and cathepsin D, must play critical role in pathways
important for the normal development and survival of neurons.
More and less systematic strategies have been utilized in attempts
to dissect the disturbed metabolic pathways in NCL. To date, the
data obtained from transcript and lipidomic profiling have
provided information on the role of lipid metabolism, synaptic
membrane trafficking and inflammationmediated neuronal death,
especially in the Cln1 deficient mouse models [32,62,104].
Changes in glutamate utilization has been a common theme
emerging from the transcript and metabolic profiling of Cln3
deficient mice and also in human samples [62–64,108].
Importantly, “metabolomics”-based screening of amino acids in
the sera of JNCLpatients led to the discovery of defective arginine
transport [27,29,110]. The transcript profiling of Cln5 deficient
mice further suggested astrocytic activation and defects in
myelinization [36]. Finally, the profiling of lipids and metabolites
in the CLN8 have highlighted severe aberrations in the lipid
profiles of human autopsied brains and changes in glutamate
metabolism in the mnd mouse [92,113] (Fig. 1). The data so far
collectedwith system-based tools have been encouraging but only
rarely exposed totally new metabolic routes or tissue-specific
consequences of NCL mutations. However, these initial findings
should stimulate further system-wide analyses of the currently
existing NCL models in experimental species.
Setting technical, statistical and biocomputational challenges
aside, any systematic comparisons of the genome-wide data
obtained from the different NCL mouse models and human
samples have been hampered by biology-related and data
integration problems. The targeted mouse mutants have been
produced using different genetic backgrounds, complicating theobal analyses in NCL.
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sampling, known to be important for correctly aimed compar-
ative statistical analyses have been lacking, partly due to
utilization of human autopsy samples. To initialize the
harmonization of sample collection, the European Commission
funded NCL models research consortium (www.nclmodels.org)
has taken the task to breed the NCL mouse into the same genetic
background (C57/BL) to provide a platform for more feasible
comparisons [136].
Key goals of future NCL research include detailed
characterization of the perturbed metabolic and transcriptional
pathways using powerful “omics” technologies. Comparative
transcriptome and proteome analyses in mammals are very
limited, but evidence suggests a close correlation between
mRNA and protein expression for the majority of genes [137].
To date it is clear that the proteomics technology lies somewhat
behind the transcript profiling, but efficient methods for the
analysis of sample quality as well as for the 2D gel
electrophoresis have recently emerged [138]. Technologies for
lipid and metabolite profiling do exist and their efficient
utilization in NCL research only lacks systematic experimen-
tation and data integration. Novel approaches have already been
introduced for data processing and analysis and data integration
will be a challenging task to combine gene expression profiling,
proteomic and metabolite analyses.Fig. 2. Future prospects for global analyses of molecular pathways esseInformation about global analyses is critical for understand-
ing the molecular mechanisms underlying a disease. For NCL,
the development of different model organisms will be crucial
for the success of the systematic strategies. To date, yeast,
nematode andDrosophilamodels exist only for CLN1 or CLN3
diseases [26,139–143]. Besides producing novel data, it is
important to utilize the existing information available in
different databases, providing an integrated view of genome-
wide information for the different model organisms [144–150].
Additionally, databases of the abnormal histology associated
with spontaneous and induced mutations of mice and other
organisms produced by transgenesis, targeted mutagenesis and
chemical mutagenesis exist, and also these can be utilized to
expedite the dissection of different disease phenotypes [151].
The mouse brain analytics should be simplified by utilization of
stereological methods as well as 3D brain mapping to first
identify the affected brain areas [60]. Additionally, the yeast,
nematode and Drosophila models offer efficient systems to
track genetic interactions [152,153]. Further, detailed analyses
of the genome-wide expression data of the model organisms are
needed to identify other genes co-regulated with the NCL genes.
One could foresee the combined analyses of the global
information of NCL (Fig. 2) as an avenue to resolve the disease
mechanisms behind these devastating disorders. Furthermore,
innovative use of these new analytic possibilities has highntial for the development and maintenance of the nervous system.
941A. Jalanko et al. / Biochimica et Biophysica Acta 1762 (2006) 934–944potential to create new understanding of neuronal development
and premature neuronal death in general.
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